# Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

> **NCT03402399** · NA · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 222 (estimated)

## Conditions studied

- Myelofibrosis, Primary
- Myelofibrosis, Post PV
- Myelofibrosis, Post ET

## Interventions

- **OTHER:** Molecular analysis

## Key facts

- **NCT ID:** NCT03402399
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-10
- **Primary completion:** 2019-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402399, "Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03402399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*